Structure-activity relationships of 2,4-diphenyl-1H-imidazole analogs as CB2 receptor agonists for the treatment of chronic pain

Shu-Wei Yang; Jennifer Smotryski; Julius Matasi; Ginny Ho; Deen Tulshian; William J Greenlee; Rossella Brusa; Massimiliano Beltramo; Kathleen Cox

doi:10.1016/j.bmcl.2010.11.044

Structure-activity relationships of 2,4-diphenyl-1H-imidazole analogs as CB2 receptor agonists for the treatment of chronic pain

Bioorg Med Chem Lett. 2011 Jan 1;21(1):182-5. doi: 10.1016/j.bmcl.2010.11.044. Epub 2010 Nov 11.

Authors

Shu-Wei Yang¹, Jennifer Smotryski, Julius Matasi, Ginny Ho, Deen Tulshian, William J Greenlee, Rossella Brusa, Massimiliano Beltramo, Kathleen Cox

Affiliation

¹ Department of Chemical Research-CV & CNS, Merck Research Laboratory, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA. shu-wei.yang@merck.com

PMID: 21115245
DOI: 10.1016/j.bmcl.2010.11.044

Abstract

A series of 2,4-diphenyl-1H-imidazole analogs have been synthesized and displayed potent human CB2 agonist activity. Many of these analogs showed high functional selectivity over human CB1 receptors. The syntheses, structure-activity relationships, and selected pharmacokinetic data of these analogs are described.

MeSH terms

Administration, Oral
Animals
Chronic Disease
Humans
Imidazoles / chemistry*
Imidazoles / pharmacokinetics
Imidazoles / therapeutic use
Pain / drug therapy*
Rats
Receptor, Cannabinoid, CB1 / agonists
Receptor, Cannabinoid, CB1 / metabolism
Receptor, Cannabinoid, CB2 / agonists*
Receptor, Cannabinoid, CB2 / metabolism
Structure-Activity Relationship

Substances

Imidazoles
Receptor, Cannabinoid, CB1
Receptor, Cannabinoid, CB2